This week in drug discovery (30 January – 3 February)

News round-up for 30 January – 3 February by DDW Digital Content Editor Diana Spencer. 

As February 4 is World Cancer Day, this week’s update focuses on developments in the field of oncology. Drugs for lung cancer, lymphoma and breast cancer have received regulatory approvals, an investment boost will allow the development of a novel approach to treating tumours, and a new global commission will seek to improve access to personalised therapies. 

The top stories: 

SMC approves targeted treatment for lung cancer 

Following a resubmission from manufacturer Merck, the Scottish Medicines Consortium (SMC) has now approved Tepmetko (tepotinib) for use on the NHS in Scotland. 

$49 million raised to fund original immuno-oncology approach 

Grey Wolf Therapeutics has closed an oversubscribed $49 million Series B financing co-led by Pfizer Ventures and Earlybird Venture Capital, with investment from Oxford Science Enterprises, British Patient Capital, Canaan and Andera Partners.    

Ground-breaking CAR-T therapy approved in UK 

Hundreds of people with an aggressive form of lymphoma are set to benefit from the first personalised immunotherapy treatment to be recommended for routine use in the NHS. 

Commission tackles global access to precision cancer treatments 

A team of experts from the University of Glasgow will lead a new international effort to improve cancer control and reduce global health inequalities. 

FDA-approved therapy targets ESR1 mutations in breast cancer 

The first and only treatment specifically indicated for patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer has been approved in the US.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free